Aclaris Therapeutics, Inc. - Special Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Aclaris Therapeutics presents positive preliminary top line data for ATI-450-RA-201. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I'd now like to hand the conference over to your speaker today, Kamil Ali-Jackson, Chief Legal Officer. Thank you. Please go ahead, ma'am.
Thank you, Shannon. I'm Kamil Ali-Jackson, Chief Legal Officer for Aclaris. Please note that earlier today, Aclaris issued its press release announcing positive preliminary top line results from its Phase IIa clinical trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450, its investigational oral MK2 inhibitor, in subjects with moderate severe rheumatoid arthritis. For those of you who have not yet seen it, you will find the release posted under the Press Releases page of the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investorsā 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |